1821. Understanding the components and calculation of the SAAR, Illustrative Data
Session: Poster Abstract Session: Antimicrobial Stewardship: New Methods and Metrics
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • Avedissian_SAAR_IDweek_ms2Updated_9_28_2018_finalDraft_ms2.pdf (560.5 kB)
  • Background: The standardized antimicrobial administration ratio (SAAR) compares each hospital’s observed to predicted days of antimicrobial therapy.  However, confusion exists about how hospital-level, seasonal, and hospital-peer-based variations in antibiotic use might impact an institution’s SAAR. We characterized the impact of each of these 3 types of variation on predicted SAARs utilizing local NHSN data.

    Methods: Analysis of antibiotic consumption data from an academic medical center in Chicago, IL was conducted. SAAR and antimicrobial days per 1000 days present (AD/1000DP) were compiled in monthly increments from 2014 to 2016. Antimicrobial consumption was aggregated and classified into agent categories according to NHSN criteria. Month-to-month changes in both the SAAR and AD/1000DP were evaluated. Azithromycin AD/1000DP from 2012 through 2017 were explored for seasonal variation as defined as >20% increase in AD/1000DP from each quarter to the overall mean AD/1000DP for all months.  A simulation was performed to explore the potential effect of seasonality on the SAAR.  Demographic covariates within the SAAR model were altered while holding constant observed antibiotic use; thus we were able to observe the potential impact of demographics.  Finally, a simulation explored the effect of altered consumption at other hospitals on a local institution’s SAAR. 

    Results: Across all antibiotic agent categories for both ICU (n=4) and general wards (n=4), the average matched-month percent change in AD/1000DP was highly predicted and correlated with the corresponding change in SAAR (Figure 1, Pearson’s r = 0.99).  The monthly mean±SD AD/1000DP was 235.0 (range 47.2-661.5), and the mean±SD SAAR was 1.09±0.26 (range 0.79-1.09) across the NHSN antibiotic agent categories.  Five quarters were found to have seasonal variation in AD/1000DP for azithromycin (Figure 2). Simulations demonstrated that changing antimicrobial usage at comparator hospitals does not impact the local SAAR, and seasonal variation may cause fluctuating SAARs.

    Conclusion: Month-to-month changes in the SAAR mirror monthly changes in an institution’s AD/1000DP.  Seasonal variation can impact the SAAR, and the effect changing peer hospital antibiotic consumption is not currently captured by the SAAR methodology. 

    Sean Avedissian, Pharm.D.1, Nathaniel Rhodes, PharmD, MSc2, Jiajun Liu, PharmD3, Doaa Aljefri, PharmD, MSc2, Michael Postelnick, RPh BCPS AQ ID2, Sarah Sutton, MD4, Teresa Zembower, MD, MPH, FIDSA4, David Martin, PharmD5, Gwendolyn Pais, PhD6, Caroline Cruce, PharmD5 and Marc H. Scheetz, PharmD, MSc, BCPS AQ-ID2, (1)Pharmacy Practice, Midwestern University Chicago College of Pharmacy/Northwestern Memorial Hospital, Downers Grove, IL, (2)Department of Pharmacy, Northwestern Medicine, Chicago, IL, (3)Pharmacy, Edward Hines, Jr. VA Hospital, Hines, IL, (4)Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, (5)Northwestern, Chicago, IL, (6)Midwestern University, Downers Grove, IL

    Disclosures:

    S. Avedissian, None

    N. Rhodes, None

    J. Liu, Merck: Grant fund from Merck , Research grant .

    D. Aljefri, None

    M. Postelnick, None

    S. Sutton, None

    T. Zembower, None

    D. Martin, Syneos Health: Employee , Salary . GlaxoSmithKline: Independent Contractor , Salary .

    G. Pais, None

    C. Cruce, None

    M. H. Scheetz, Merck & Co., Inc.: Grant Investigator , Grant recipient . Bayer: Consultant , Consulting fee .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.